Prism Health, Inc.

Prism Health specializes in streamlining clinical trials through an AI-powered operating system called prismOS, aiming to optimize efficiency and reduce costs in the clinical research sector. Prism Health, Inc. was founded in 2025 in Austin, US, focusing on the automation of clinical trial processes. The company has successfully completed a total of 1 deal, raising USD 200,000 in pre-seed funding from Antler on April 9, 2025.

The firm is not reported to have any subsidiaries or parent companies. Prism Health specializes in providing an AI-powered operating system for clinical trials, known as prismOS. This platform is designed to optimize the clinical trial process by automating various tedious and costly components, facilitating faster and more cost-effective trials. Core offerings include end-to-end trial services that encompass expert protocol design, regulatory pathway planning, and study feasibility assessments.

The platform supports real-time monitoring of patient recruitment and provides on-demand access to trial data and automated workflows, thereby addressing the needs of clinical research sponsors across diverse sectors. Prism Health primarily serves medical technology sponsors, clinical research organizations, and academic institutions, with a focus on enhancing the operational efficiency of clinical trials across North America and Europe. Prism Health operates on a fixed-price model, allowing clients to pay for only the services they require, tailored to their specific needs. The company's revenue generation relies on structured transactions for its trial services, which include patient enrollment, laboratory processing, and imaging services.

Patient enrollment is priced at USD 1,500 per subject, MRI scans at USD 800 each, and lab processing fees at USD 100 per test. This pricing structure reflects the company's commitment to delivering high-quality services while maintaining cost transparency for its clients. The company’s business model primarily caters to B2B relationships, directly engaging with sponsors and research institutions to streamline their clinical trial processes. Prism Health plans to utilize the recent funding of USD 200,000 raised in April 2025 to support the development of new features within the prismOS platform and enhance its existing offerings.

The firm is also exploring opportunities to expand its services into new regions, particularly in Europe, by the end of 2025 as part of its strategic growth initiatives.